ELPIS II Misses Its Phase IIb Ventricular Endpoint
Laromestrocel did not improve the primary Month-12 right-ventricular ejection-fraction endpoint in the randomized, 40-infant ELPIS II study of hypoplastic left heart syndrome. The least-squares mean difference was -0.7 percentage points versus surgery alone, with…
